We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthpeak Amends & Extends Lease With Amgen in San Francisco
Read MoreHide Full Article
Healthpeak Properties, Inc. recently announced a lease amendment and extension with Amgen (AMGN - Free Report) on the Britannia Oyster Point ("BOP") campus of the former in South San Francisco. The move marks the company’s efforts to continue its strategic relationships with existing tenants as well as address future tenants looking for space at this property.
Presently, Amgen leases spaces across the BOP campus in seven buildings. These include 1130 & 1150 Veterans Blvd, 331 & 333 Oyster Point Blvd, as well as 1100, 1120 and 1140 Veterans Blvd.
With the lease amendment, Amgen has the flexible right to carry on its occupancy at three of its currently-leased buildings through 2029. At the same time, Amgen has flexibility to end its occupancy in these buildings at prior dates, which is conditional on advance notice requirements.
Located in a thriving development area, the BOP campus has 10 buildings aggregating more than 900,000 square feet of Class-A life-sciences spaces. It is positioned directly neighboring to Healthpeak's transformative 1-million-square-foot development — The Cove at Oyster Point.
Notably, over the past years, Healthpeak has made concerted efforts to reposition its portfolio. As part of these, the company has recycled capital through non-core dispositions to its solid investment and development pipeline. The strategic expansion of its life-science and medical office building (MOB) portfolio footprint and selective buyouts of high-quality senior housing assets in high barrier-to-entry markets has renewed the company’s growth opportunities.
Increasing life expectancy of the U.S. population and bio-pharma drug development growth opportunities have boosted the institutional life-science and medical-real estate market fundamentals. Amid these, Healthpeak has adopted a cluster strategy in three premier life-science epicenters — San Diego, San Francisco and Boston — aimed at assembling assets through acquisitions, developments and redevelopments. On the back of these, the company is gaining scale and is well poised to meet the growing demand of life-science tenants.
Healthpeak currently carries a Zacks Rank #3 (Hold). In the past six months, shares of this REIT have gained 8.4%, as against its industry’s increase of 2.3%.
Stocks to Consider
Prologis, Inc.’s (PLD - Free Report) currently sports a Zacks Rank of 1 (Strong Buy). The company’s funds from operations (FFO) per share estimate for 2019 has been revised 1.2% upward to $3.31 in two months’ time. The stock has rallied 10.8% in three months’ time. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cousins Properties Incorporated’s (CUZ - Free Report) Zacks Consensus Estimate for the current-year FFO per share moved 2.1% north to $2.96 over the past two months. Shares of this Zacks Rank #2 (Buy) company have gained 12% over the past three months.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Image: Bigstock
Healthpeak Amends & Extends Lease With Amgen in San Francisco
Healthpeak Properties, Inc. recently announced a lease amendment and extension with Amgen (AMGN - Free Report) on the Britannia Oyster Point ("BOP") campus of the former in South San Francisco. The move marks the company’s efforts to continue its strategic relationships with existing tenants as well as address future tenants looking for space at this property.
Presently, Amgen leases spaces across the BOP campus in seven buildings. These include 1130 & 1150 Veterans Blvd, 331 & 333 Oyster Point Blvd, as well as 1100, 1120 and 1140 Veterans Blvd.
With the lease amendment, Amgen has the flexible right to carry on its occupancy at three of its currently-leased buildings through 2029. At the same time, Amgen has flexibility to end its occupancy in these buildings at prior dates, which is conditional on advance notice requirements.
Located in a thriving development area, the BOP campus has 10 buildings aggregating more than 900,000 square feet of Class-A life-sciences spaces. It is positioned directly neighboring to Healthpeak's transformative 1-million-square-foot development — The Cove at Oyster Point.
Notably, over the past years, Healthpeak has made concerted efforts to reposition its portfolio. As part of these, the company has recycled capital through non-core dispositions to its solid investment and development pipeline. The strategic expansion of its life-science and medical office building (MOB) portfolio footprint and selective buyouts of high-quality senior housing assets in high barrier-to-entry markets has renewed the company’s growth opportunities.
Increasing life expectancy of the U.S. population and bio-pharma drug development growth opportunities have boosted the institutional life-science and medical-real estate market fundamentals. Amid these, Healthpeak has adopted a cluster strategy in three premier life-science epicenters — San Diego, San Francisco and Boston — aimed at assembling assets through acquisitions, developments and redevelopments. On the back of these, the company is gaining scale and is well poised to meet the growing demand of life-science tenants.
Healthpeak currently carries a Zacks Rank #3 (Hold). In the past six months, shares of this REIT have gained 8.4%, as against its industry’s increase of 2.3%.
Stocks to Consider
Prologis, Inc.’s (PLD - Free Report) currently sports a Zacks Rank of 1 (Strong Buy). The company’s funds from operations (FFO) per share estimate for 2019 has been revised 1.2% upward to $3.31 in two months’ time. The stock has rallied 10.8% in three months’ time. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cousins Properties Incorporated’s (CUZ - Free Report) Zacks Consensus Estimate for the current-year FFO per share moved 2.1% north to $2.96 over the past two months. Shares of this Zacks Rank #2 (Buy) company have gained 12% over the past three months.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
See their latest picks free >>